Shopping Cart
- Remove All
![TargetMol](https://www.targetmol.com/storage/error/oops.webp)
Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $1,520 | 6-8 weeks | |
50 mg | $1,980 | 6-8 weeks | |
100 mg | $2,500 | 6-8 weeks |
Description | Nuvenzepine is an antagonist of mAChR. It has the potential for gastrospasm treatment. |
In vitro | Nuvenzepine demonstrates nearly equal potency to pirenzepine in competitively inhibiting bethanechol-induced gallbladder contractions and exhibits a four-fold greater potency in preventing vagal-stimulated tracheal constrictions. Additionally, it has a four-fold higher affinity than pirenzepine in competitively antagonizing acetylcholine-induced contractions in both isolated ileal musculature and longitudinal ileum dispersed cells [1]. |
In vivo | Nuvenzepine, distinct from pirenzepine, actively moderates colonic motility and, when administered intraduodenally in anaesthetized cats, exhibits a prolonged, dose-dependent suppression of neostigmine-induced intestinal movement. This compound significantly reduces gastric acid secretion and intestinal hypermotility in rats while manifesting minimal atropine-like side effects. It is characterized by slow oral absorption, with an absolute bioavailability of 30 to 40%, slow elimination, negligible accumulation in the body, and minimal metabolism. Notably, Nuvenzepine's efficacy in inhibiting ileal motor activity is tenfold that of pirenzepine and demonstrates a 25-30 times higher potency in suppressing pentagastrin-stimulated gastric acid secretion in conscious cats, indicating its significant therapeutic potential. |
Molecular Weight | 336.39 |
Formula | C19H20N4O2 |
Cas No. | 96487-37-5 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.